Jupiter Neurosciences, Inc. develops JOTROL™, a patented resveratrol-based platform used in its clinical-stage neuroinflammation pipeline and Nugevia™ consumer longevity products. Company news centers on CNS and rare-disease development, including Parkinson’s disease work, and on commercialization of Nugevia formulations for mitochondrial support, cognitive health and skin vitality.
Recurring updates also cover investor-conference presentations, practitioner and wellness-channel initiatives, advisory-board additions, financing arrangements tied to convertible notes and a standby equity purchase agreement, and Nasdaq listing-compliance matters affecting its common stock.
Jupiter Neurosciences (JUNS) has announced the pricing of its initial public offering of 2,750,000 shares at $4.00 per share, expecting to raise $11 million in gross proceeds. Trading will commence on Nasdaq Capital Market on December 3, 2024, under the symbol 'JUNS'. The company plans to use proceeds to fund Phase II clinical trials of JOTROL™ for Parkinson's Disease, expand business in South-East Asia, conduct R&D, pay license fees to Aquanova AG, repay debt, and support working capital. The offering is led by Dominari Securities with Revere Securities as co-manager.